165 related articles for article (PubMed ID: 37634629)
1. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract][Full Text] [Related]
3. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
5. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
[TBL] [Abstract][Full Text] [Related]
7. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.
Xi W; Zhou C; Xu F; Sun D; Wang S; Chen Y; Ji J; Ma T; Wu J; Shangguan C; Zhu Z; Zhang J
J Transl Med; 2022 Aug; 20(1):365. PubMed ID: 35962408
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis.
Hyung J; Lee JY; Kim JE; Yoon S; Yoo C; Hong YS; Jeong JH; Kim TW; Jeon S; Jun HR; Jung CK; Jang JP; Kim J; Chun SM; Ahn JH
ESMO Open; 2023 Jun; 8(3):101583. PubMed ID: 37327700
[TBL] [Abstract][Full Text] [Related]
10. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
12. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
13. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
[TBL] [Abstract][Full Text] [Related]
15. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
Wang DS; Liu ZX; Lu YX; Bao H; Wu X; Zeng ZL; Liu Z; Zhao Q; He CY; Lu JH; Wang ZQ; Qiu MZ; Wang F; Wang FH; Li YH; Wang XN; Xie D; Jia WH; Shao YW; Xu RH
Gut; 2019 Jul; 68(7):1152-1161. PubMed ID: 30269082
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies.
Zhang C; Chen Z; Chong X; Chen Y; Wang Z; Yu R; Sun T; Chen X; Shao Y; Zhang X; Gao J; Shen L
Clin Transl Med; 2020 Dec; 10(8):e254. PubMed ID: 33377634
[TBL] [Abstract][Full Text] [Related]
18. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
20. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
